Clinical Trial Update: Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia [Phase 2]

View source ↗

Summary

Phase 2 multiple ascending dose study of IBI306 (a PCSK-9 inhibitor) in Chinese patients with hypercholesterolemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• IBI306

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED